Sign inCreate account

Report workspace tools

NCT05576324UNKNOWNanonymous

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor on Numerical Distribution in Peripheral Mononuclear Immune Cells Derived From Patients With Cystic Fibrosis

Sponsor

Source record

University of Erlangen-Nürnberg Medical School

Phase

Source record

Not classified

Modality

AI-normalized

small molecule

Target

AI-normalized

Elexacaftor / Ivacaftor / Tezacaftor

Indication / condition

AI-normalized

Cystic Fibrosis

Intervention

Source record

Elexacaftor / Ivacaftor / Tezacaftor

Source & freshness

Source record

NCT ID

NCT05576324

Original source

ClinicalTrials.gov

Source last updated

Oct 12, 2022

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05576324

Title

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor on Numerical Distribution in Peripheral Mononuclear Immune Cells Derived From Patients With Cystic Fibrosis

Sponsor

University of Erlangen-Nürnberg Medical School

Status

UNKNOWN

Phase

Detailed source ingestion pending

Condition raw

Cystic Fibrosis

Condition normalized

Cystic Fibrosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Elexacaftor / Ivacaftor / Tezacaftor

Target normalized

Elexacaftor / Ivacaftor / Tezacaftor

Interventions

Elexacaftor / Ivacaftor / Tezacaftor

Public preview

Source record

The aim of this study is to investigate the frequency distribution, cytokine profile and function of peripheral, mononuclear leukocyte populations (monocytes, NK cells, T/B lymphocytes) and their correlation to clinical and biochemical parameters in patients with cystic fibrosis receiving CFTR modulatory triple therapy consisting of elexacaftor, tezacaftor and ivacaftor and to compare it with patients without CFTR modulatory therapy and healthy control subjects.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor on Numerical Distribution in Peripheral Mononuclear Immune Cells Derived From Patients With Cystic Fibrosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05576324

Status

UNKNOWN

Phase

N/A

Sponsor

University of Erlangen-Nürnberg Medical School

Executive brief

Investment-Ready Snapshot

The aim of this study is to investigate the frequency distribution, cytokine profile and function of peripheral, mononuclear leukocyte populations (monocytes, NK cells, T/B lymphocytes) and their correlation to clinical and biochemical parameters in patients with cystic fibrosis receiving CFTR modulatory triple therapy consisting of elexacaftor, tezacaftor and ivacaftor and to compare it with patients without CFTR modulatory therapy and healthy control subjects.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 12, 2022
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05576324

Indication

Cystic Fibrosis

Modality

small molecule

Target

Elexacaftor / Ivacaftor / Tezacaftor

Intervention

Elexacaftor / Ivacaftor / Tezacaftor

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.